Zoetis (NYSE:ZTS) Trading Down 0.4%

Shares of Zoetis Inc. (NYSE:ZTS - Get Free Report) traded down 0.4% during trading on Monday . The company traded as low as $145.97 and last traded at $145.97. 964,659 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 3,003,641 shares. The stock had previously closed at $146.50.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 20th. The Goldman Sachs Group increased their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a "buy" rating in a research note on Wednesday, January 17th. Barclays lifted their price objective on Zoetis from $255.00 to $260.00 and gave the company an "overweight" rating in a research report on Wednesday, February 14th. Piper Sandler reissued an "overweight" rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus lowered their target price on Zoetis from $215.00 to $195.00 and set a "buy" rating for the company in a research note on Tuesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $221.75.

Zoetis Trading Down 0.7 %

The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The firm has a market cap of $66.56 billion, a PE ratio of 28.79, a price-to-earnings-growth ratio of 2.24 and a beta of 0.85. The stock has a 50-day simple moving average of $175.48 and a two-hundred day simple moving average of $180.15.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts' consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the firm posted $1.15 EPS. The company's revenue for the quarter was up 8.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.19%. Zoetis's dividend payout ratio (DPR) is 34.12%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 in the last 90 days. Company insiders own 0.15% of the company's stock.

Hedge Funds Weigh In On Zoetis

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Zoetis by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company's stock worth $7,960,912,000 after purchasing an additional 536,477 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company's stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company's stock valued at $2,147,730,000 after purchasing an additional 297,044 shares in the last quarter. Capital World Investors raised its stake in Zoetis by 0.6% during the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company's stock valued at $1,788,988,000 after purchasing an additional 57,798 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company's stock valued at $1,068,804,000 after buying an additional 196,771 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.